Optovue Showcases Retinal Blood Flow Measurement Capability for Improving Management of Diabetes-Related Vision Loss

AngioAnalytics, World’s First OCT Angiography Quantification
Technology, Announced at Prestigious European Society for Cataract and
Refractive Surgery

FREMONT, Calif. & BARCELONA, Spain–(BUSINESS WIRE)–Optovue, the global leader in the development and commercialization of
optical coherence tomography angiography (OCTA), today announced
AngioAnalytics™, a significant expansion of its OCTA technology, at the
33rd congress of the European Society for Cataract and
Refractive Surgery (ESCRS) being held in Barcelona, Spain from September
5-9. This new capability will provide clinicians with the ability to
quantify the density of blood flow in the retina, the light-sensitive
portion of the eye.

“For the first time ever, ophthalmologists will have the ability to
detect early, and manage more closely, devastating eye diseases by
viewing the density of blood vessels in the retina and measuring the
presence or absence of blood flow,” said Dr. Richard Rosen, MD, FACS,
FASRS, CRA, Professor of Ophthalmology and Director or Retina at the New
York Eye and Ear Infirmary. “AngioAnalytics expands OCTA technology by
introducing quantification so that changes to a patient’s retina can be
tracked objectively, potentially even before the patient notices
significant vision degradation. This capability allows us to optimize
treatment in a way that we have not previously been able to do, and may
lead to changes in the clinical management of diabetic retinopathy,
age-related macular degeneration, and other diseases that cause
progressive vision loss.”

The AngioVue™ Imaging System embodies OCTA technology, which uses light
rays to form detailed three-dimensional images of the retina so
physicians can quickly visualize the anatomic structures and any
abnormalities present. In less than three seconds, the AngioVue System
acquires a single image that complements, and in some cases can replace,
the current angiography imaging standard, fluorescein angiography (FA),
but with a number of advantages. Unlike FA, the AngioVue System is
non-invasive and does not require the use of dye injections, which can
often obscure the target anatomy, leading to diagnostic uncertainty. The
addition of AngioAnalytics to the AngioVue system now provides objective
data regarding the areas encompassed by flow and non-flow regions, and
creates a visual map of the blood flow in the retina.

Diabetic retinopathy is characterized by a predictable progression of
vascular changes in the circulation of the retina ultimately leading to
areas without any blood flow at all. In later stages of the disease, the
growth of new blood vessels occurs along with an overall thickening of
the central part of the retina. According to the World Health
Organization, diabetic retinopathy is responsible for nearly two million
cases of blindness globally. Age-related macular degeneration is the
third leading cause of blindness in the world, and is characterized by a
loss of vision in the central visual field.

“Providing clinicians with the ability to quantify blood flow in the
retina should allow for earlier and more individualized treatment,
without the need or cost of repeated dye injections,” said Jay Wei,
founder and chief executive officer for Optovue. “We are very pleased
with the adoption and utilization of the AngioVue System since its
introduction last year, and we expect AngioAnalytics to further its
momentum.”

Recent clinical findings from the AngioVue Imaging System will be
highlighted in a symposium entitled, “New Technology for Imaging
Structure and function from cornea to Retina,” on Saturday, Sept. 5 at
6:00 pm at the Hotel Fira Congress Barcelona. Additionally
demonstrations of the system will be held throughout the congress in the
Optovue booth #D06 located in exhibit hall 7.

About Optovue

Optovue, Inc., a privately-held medical device company founded in 2003
and based in Fremont, Calif., is dedicated to the development and
commercialization of high-speed optical coherence technology used to
facilitate the diagnosis and management of eye diseases, many of which
may lead to permanent blindness. Since its introduction, the AngioVue
Imaging System has been incorporated in to daily clinical use at over
350 sites worldwide. For more information, visit www.optovue.com.

The AngioVue Imaging System and AngioAnalytics require regulatory
approval, and are not currently available in the United States.

Contacts

For Optovue:
Christina Kirby, 510-857-9704
Marketing Director
Christina_Kirby@Optovue.com